References

  1. Where Aspergillosis Comes From. (2021, January 8, 2021). https://www.cdc.gov/fungal/diseases/aspergillosis/causes.html
  2. Kwon-Chung, K. J., & Sugui, J. A. (2013). Aspergillus fumigatus—what makes the species a ubiquitous human fungal pathogen? PLoS Pathog, 9(12), e1003743. https://doi.org/10.1371/journal.ppat.1003743
  3. Kousha, M., Tadi, R., & Soubani, A. O. (2011). Pulmonary aspergillosis: a clinical review. Eur Respir Rev, 20(121), 156-174. https://doi.org/10.1183/09059180.00001011
  4. Koehler, P., Bassetti, M., Chakrabarti, A., et al. (2021). Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis, 21(6), e149-e162. https://doi.org/10.1016/ S1473-3099(20)30847-1
  5. Taccone, F. S., Van den Abeele, A. M., Bulpa, P., et al. (2015). Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes. Crit Care, 19(1), 7. https://doi.org/10.1186/s13054-014-0722-7
  6. Kosmidis, C., & Denning, D. W. (2015). The clinical spectrum of pulmonary aspergillosis. Thorax, 70(3), 270-277. https://doi.org/10.1136/thoraxjnl-2014-206291
  7. Chabi, M. L., Goracci, A., Roche, N., et al. (2015). Pulmonary aspergillosis. Diagn Interv Imaging, 96(5), 435-442. https://doi.org/10.1016/j.diii.2015.01.005
  8. Denning, D. W., Cadranel, J., Beigelman-Aubry, C., et al. (2016). Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J, 47(1), 45-68. https://doi.org/10.1183/13993003.00583-2015
  9. Patterson, T. F. (2022). Treatment and prevention of invasive aspergillosis. In C. A. Kauffman (Ed.). UpToDate.
  10. CRESEMBA® (isavuconazonium sulfate) capsules, injection [prescribing information]. Northbrook, IL: Astellas Pharma US; November 2022. Accessed on February 16, 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8f7f73b8-586a-4df0-935f-fecd4696c16c
  11. Cronin, S., & Chandrasekar, P. H. (2010). Safety of triazole antifungal drugs in patients with cancer. J Antimicrob Chemother, 65(3), 410-416. https://doi.org/10.1093/jac/dkp464
  12. Murray, A., Cass, L., Ito, K., et al. (2020). PC945, a Novel Inhaled Antifungal Agent, for the Treatment of Respiratory Fungal Infections. J Fungi (Basel), 6(4). https://doi.org/10.3390/jof6040373
  13. Vallabhaneni, S., Benedict, K., Derado, G., et al. (2017). Trends in Hospitalizations Related to Invasive Aspergillosis and Mucormycosis in the United States, 2000-2013. Open Forum Infect Dis, 4(1), ofw268. https://doi.org/10.1093/ofid/ofw268
  14. Colley, T., Alanio, A., Kelly, S. L., et al. (2017). In Vitro and In Vivo Antifungal Profile of a Novel and Long-Acting Inhaled Azole, PC945, on Aspergillus fumigatus Infection. Antimicrob Agents Chemother, 61(5). https://doi.org/10.1128/AAC.02280-16
  15. Logan, A., Wolfe, A., & Williamson, J. C. (2022). Antifungal Resistance and the Role of New Therapeutic Agents. Curr Infect Dis Rep, 24(9), 105-116. https://doi.org/10.1007/s11908-022-00782-5
  16. Ito, K. (2022). Inhaled antifungal therapy: benefits, challenges, and clinical applications. Expert Opin Drug Deliv, 19(7), 755-769. https://doi.org/10.1080/17425247.2022.2084530
  17. Cass, L., Murray, A., Davis, A., et al. (2021). Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent. Pharmacol Res Perspect, 9(1), e00690. https://doi.org/10.1002/prp2.690
  18. Pagani, N., Armstrong-James, D., & Reed, A. (2020). Successful salvage therapy for fungal bronchial anastomotic infection after -lung transplantation with an inhaled triazole anti-fungal PC945. J Heart Lung Transplant, 39(12), 1505-1506. https://doi.org/10.1016/j.healun.2020.09.015
  19. Wenzler, E., Fraidenburg, D. R., Scardina, T., et al. (2016). Inhaled Antibiotics for Gram-Negative Respiratory Infections. Clin Microbiol Rev, 29(3), 581-632. https://doi.org/10.1128/CMR.00101-15
  20. Kimura, G., Nakaoki, T., Colley, T., et al. (2017). In Vivo Biomarker Analysis of the Effects of Intranasally Dosed PC945, a Novel Antifungal Triazole, on Aspergillus fumigatus Infection in Immunocompromised Mice. Antimicrob Agents Chemother, 61(9). https://doi.org/10.1128/AAC.00124-17
  21. MHRA. (2014). The supply of unlicensed medicinal products (“specials”). Retrieved from https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/373505/The_supply_of_unlicensed_medicinal_products__specials_.pdf
  22. Singh, S., Moore, L. S. P., Mughal, N., et al. (2023). Novel inhaled antifungal for pseudomembranous Aspergillus tracheobronchitis complicating connective tissue disease. Thorax, 78(1), 110-111. https://doi.org/10.1136/thorax-2021-218375

IMAGE REFERENCES

  • About Aspergillosis Image source: Prasad, A., Agarwal, K., Deepak, D., et al. (2016). Pulmonary Aspergillosis: What CT can Offer Before it is too Late! J Clin Diagn Res, 10(4), TE01-05. https://doi.org/10.7860/JCDR/2016/17141.7684
  • Data on file
  • Zhou, L. H., Jiang, Y. K., Li, R. Y., et al. (2020). Risk-Based Estimate of Human Fungal Disease Burden, China. Emerg Infect Dis, 26(9), 2137-2147. https://doi.org/10.3201/eid2609.200016
Scroll to Top